A Diagnostics & Imaging Week Daily
Fujirebio Diagnostics (Malvern, Pennsylvania), a maker of cancer diagnostics and biomarker assays, reported that it has acquired American Biological Technologies (ABT; Seguin, Texas), a manufacturer of in vitro diagnostic assay controls and calibrators. Financial terms were not disclosed.
Fujirebio said the deal marks its entry into the controls and calibrators manufacturing business, enabling it to strengthen its position in the in vitro diagnostics industry, it said.
"The acquisition is a natural next step on our path in entering diagnostic assay control and calibrator manufacturing, and mirrors Fujirebio Diagnostics' strategy to provide its diagnostic industry customers with the tools and services that will revolutionize how disease is diagnosed and managed," said Paul Touhey, president/CEO of Fujirebio.
ABT has been one of Fujirebio's main suppliers, providing controls and calibrators to a shared customer base. Controls and calibrators are used to confirm that diagnostic assay kits and the analyzers that the kits run on are performing within specification, thus complementing Fujirebio's portfolio of diagnostic assays.
In other dealmaking:
• Solis Women's Health (Austin, Texas) reported acquiring MedTech Mammography Centers (Phoenix), an independent provider of screening mammography in the Southwest. The MedTech complex includes seven facilities in greater Phoenix and three in Tucson. Terms were not disclosed.
Solis CEO Brad Hummel said the acquisition "dramatically increases our reach in Phoenix and Tucson . . . . Each of these facilities offers full field digital mammography and will quickly be integrated into the Solis network."
Solis is a provider of screening mammography, diagnostic mammography, computer–aided detection, breast ultrasound, bone densitometry and stereotactic and ultrasound–guided biopsy, breast specific gamma imaging and breast MRI.
• The board of Molecular Vision (London) reported that discussions concerning its acquisition by Acrongenomics (Geneva, Switzerland) have ended. It said Acrongenomics has been unable to complete the deal on the agreed–upon terms and timetable.
Molecular Vision's board said "the best interests of the company are served by bringing these discussions to a conclusion."
Acrongenomics remains a significant shareholder in Molecular Vision, having recently acquired a 10.9% stake in the company, and that work continues on a joint development agreement between the companies begun in March 2006.
Molecular Vision is a developer of credit–card sized devices for medical testing to extend the in–house tools available to the general practitioner and allow near–patient quantitative diagnosis, currently focusing on key areas of high disease burden, namely kidney function and cardiovascular disease.